1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Infinity to raise $77m from stock offer in wake of layoffs

 
• By Mandy Jackson

Infinity Pharmaceuticals priced a 5.3 million-share common stock offering at $14.50 per share on 9 August for gross proceeds of $76.9 million to fund research and development for its two lead product candidates and other expenses two days after it announced a 20% work force reduction at its Cambridge, Massachusetts headquarters (scripintelligence.com, 9 August 2012).

Infinity Pharmaceuticals priced a 5.3 million-share common stock offering at $14.50 per share on 9 August for gross proceeds of $76.9 million to fund research and development for its two lead product candidates and other expenses two days after it announced a 20% work force reduction at its Cambridge, Massachusetts headquarters (scripintelligence.com, 9 August 2012).

While investors generally respond to offerings at a discount to the stock's current trading price by sending the company's share...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

GSK’s Blenrep US Setback Could Go From Bad To Worse

 
• By Sushmita Panda

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 
• By Alaric DeArment

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.

More from Therapeutic Category

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.